Structure-based design, synthesis and biological evaluation of β-glucuronidase inhibitors

Journal of Computer-Aided Molecular Design

Volumn 28, Issue 5, 2014, Pages 577-585

  Khan, Khalid M ^a   Ambreen, Nida ^a   Taha, Muhammad ^b,c   Halim, Sobia A ^a   Zaheer Ul Haq, ^a   Naureen, Shagufta ^a   Rasheed, Saima ^a   Perveen, Shahnaz ^d   Ali, Sajjad ^e   Choudhary, Mohammad Iqbal ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b Puncak Alam Campus ^*  (Malaysia)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^d PCSIR LABORATORIES COMPLEX   (Pakistan)

^e KARAKORAM INTERNATIONAL UNIVERSITY   (Pakistan)

Author keywords

Coumarin derivative; Docking study; Glucuronidase

Indexed keywords

BIOLOGICAL EVALUATION; COUMARIN DERIVATIVES; DESIGN EVALUATION; DESIGN SYNTHESIS; DOCKING STUDIES; GLUCURONIDASE; STRUCTURE-BASED DESIGNS; SYNTHESIS EVALUATION; SYNTHETIC COMPOUNDS; Β-GLUCURONIDASE;

BETA GLUCURONIDASE; BETA GLUCURONIDASE INHIBITOR; COUMARIN DERIVATIVE; ENZYME INHIBITOR; TRITON X 100; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; COMPUTER AIDED DESIGN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; IC50; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; GLUCURONIDASE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 84904440676     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-014-9745-z     Document Type: Article

References (46)

1. Paigen K (1989) Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology. Prog Nucl Acid Res Mol Biol 37:155-205
2. Islam MR, Grubb JH, Sly WS (1993) C-terminal processing of human beta glucuronidase. The propeptide is required for full expression of catalytic activity, intracellular retention, and proper phosphorylation. J Biol Chem 268:22627-22633 (Pubitemid 23318318)
3. Shipley JM, Grubb JH, Sly WS (1993) The role of glycosylation and phosphorylation in the expression of active human β-glucuronidase. J Biol Chem 268:12193-12198 (Pubitemid 23168188)
4. Kim HW, Mino K, Ishikawa K (2008) Crystallization and preliminary X-ray analysis of endoglucanase from Pyrococcus horikoshii". Acta Crystallogr Sect F Struct Biol Cryst Commun 64:1169-1171
5. Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, Grubb JH (1996) Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motif. Nat Struct Biol 3:375-381 (Pubitemid 26112636)
6. Sperker B, Mürdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK (1997) Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther 281:914-920 (Pubitemid 27203827)
7. Bank N, Bailine SH (1965) Urinary beta-glucuronidase activity in patients with urinary-tract infection. N Engl J Med 272:70-75
8. Roberts AP, Frampton J, Karim SM, Beard RW (1967) Estimation of beta-glucuronidase activity in urinary-tract infection. N Engl J Med 276:1468-1470
9. Ronald AR, Silverblatt F, Clark H, Cutler RE, Turck M (1971) Failure of urinary beta-glucuronidase activity to localize the site of urinary tract infection. Appl Microbiol 21:990-992
10. Kallet HA, Lapco L (1967) Urine beta glucuronidase activity in urinary tract disease. J Urol 97:352-356
11. Gonick HC, Kramer HJ, Schapiro AE (1973) Urinary β-glucuronidase activity in renal disease. Arch Intern Med 132:63-69
12. Schapiro A, Paul W, Gonick H (1968) Urinary beta-glucuronidase in urologic diseases of the kidneys. J Urol 100:146-157
13. Plum CM (1967) Beta-glucuronidase activity in serum, cerebrospinal fluid and urine in normal subjects and in neurological and mental patients. Enzymol Biol Clin 8:97-112
14. Hradec E, Petrík R, Pezlarová J (1965) The activity of beta-glucuronidase in cases of bladder neoplasms. J Urol 94:430-435
15. Boyland E, Gasson JE, Williams DC (1957) Enzyme activity in relation to cancer; the urinary beta-glucuronidase activity of patients suffering from malignant disease. Br J Cancer 11:120-129
16. Caygill JC, Pitkeathly DA (1966) BTS/BLF/BALR early career investigator of the year: a study of β-acetylglucosaminase and acid phosphatase in pathological joint fluids. Ann Rheum Dis 25:137-144
17. Weissmann G, Zurier RB, Spieler PJ, Goldstein IM (1971) Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med 134:149S-165S
18. Reddy BS (1976) Dietary factors and cancer of the large bowel. Semin Oncol 3:351-359
19. Goldin BR, Gorbach SL (1976) The relationship between diet and rat fecal bacterial enzymes implicated in colon cancer. J Nat Cancer Inst 57:371-375
20. Takada H, Hirooka T, Hiramatsu Y, Yamamoto M (1982) Effect of β-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats1. Cancer Res 42:331-334 (Pubitemid 12207287)
21. Khan KM, Shujaat S, Rahat S, Hayat S, Choudhary MI (2002) Beta-N-cyanoethyl acyl hydrazide derivatives: a new class of beta-glucuronidase inhibitors. Chem Pharm Bull 50:1443-1446 (Pubitemid 41685609)
22. Khan KM, Rahim F, Wadood A, Taha M, Khan M, Naureen S, Ambreen N, Hussain S, Perveen S, Choudhary MI (2014) Evaluation of bisindole as potent β-glucuronidase inhibitors: synthesis and in silico based studies. Bioorg Med Chem Lett 24:1825-1829
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:3-25 (Pubitemid 27046991)
24. MOE (The Molecular Operating Environment), Version 2006.08 (2007) software, Chemical Computing Group Inc., Montreal, Canada.http://www.chemcomp. com
25. SYBYL Molecular Modeling Software Packages, Version 6.9 (2004) Tripos Associates, St Louis, MO
26. http://www.iccs.edu/pcmd/compound-bank.php
27. Abid O, Babar TM, Ali FI, Ahmed S, Wadood A, Rama NH, Uddin R, Ul-Haq Zaheer, Khan A, Choudhary MI (2010) Identification of novel urease inhibitors by high-throughput virtual and in vitro screening. Med Chem Lett 1:145-149
28. GOLD Version 4.0. (2001) Astex Technology, Cambridge
29. Collins RA, Ng TB, Fong WP, Wan CC, Yeung HW (1997) Inhibition of glycohydrolase enzymes by aqueous extracts of Chinese medicinal herbs in a microplate format. Biochem Mol Biol Int 42:1163-1169 (Pubitemid 28297494)
30. Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H (2000) Antioxidative and anti-glycation activity of garcinol from Garcinia indica fruit rind. J Agric Food Chem 48:180-185 (Pubitemid 30120339)
31. Mamillapalli R, Haimovitz R, Ohad M, Shinitzky M (1998) Enhancement and inhibition of snake venom phosphodiesterase activity by lysophospholipids. FEBS Lett 436:256-258 (Pubitemid 28468567)
32. López-Gómez J, Costas MJ, Meireles RJ, Fernández A, Romero A, Ávalos M, Cameselle JC (1998) Glycine-enhanced inhibition of rat liver nucleotide pyrophosphatase/phosphodiesterase-I by EDTA: a full account of the reported inhibition by commercial preparations of acidic fibroblast growth factor (FGF-1). FEBS Lett 421:77-79 (Pubitemid 28068823)
33. Razzell WE, Khorana HG (1959) Studies on polynucleotides III. Enzymic degradation. Substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem 234:2105-2113
34. Nakabayashi T, Matsuoka Y, Ikezawa H, Kimura Y (1994) Alkaline phosphodiesterase I release from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C-IV. The release from Cavia porcellus organs. Int J Biochem 26:171-179
35. Kato K, Yoshida K, Tsukamoto H, Nobunaga M, Masuya T, Sawada T (1960) Synthesis of p-nitro phenyl beta-D-glucopyranosiduronic acid and its utilisation as substrate for assay of beta-glucuronidase activity. Chem Pharm Bull 8:239-242
36. Islam MR, Tomatsu S, Shah GN, Grubb JH, Jain S, Sly WS (1999) Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J Biol Chem 274:23451-23455
37. Kawasaki M, Hayashi T, Arisawa M, Morita N, Berganza L (1988) H.8-hydroxytricetin 7-glucuronide. A β-glucuronidase inhibitor from Scoparia dulcis. Photochemistry 27:3709-3711
38. Schmeda-Hirschmann G, Loyola JI, Reyes S, Hubert E, Rodriguez M, Rodriguez J, Dutra-Behrens M (1994) β-Glucuronidase inhibition and diuretic activity of Fabiana imbricata R. & P. (Solanaceae). Phytother Res 8:485-487
39. Hayashi T, Kawasaki M, Okamura K, Tamada Y, Morita N, Tezuka Y, Kikuchi T, Miwa Y, Taga T (1992) Scoparic acid A, A β-glucuronidase inhibitor from Scoparia dulcis. J Nat Prod 55:1748-1755 (Pubitemid 23023261)
40. Cenci di Bello I, Dorling P, Fellows L, Winchester B (1984) Specific inhibition of human β-D-glucuronidase and α-L-iduronidase by a trihydroxy pipecolic acid of plant origin. FEBS Lett 176:61-64 (Pubitemid 15203939)
41. Levy G, Conchi J (1966) β-Glucuronidase and the hydrolysis of glucuronides. In: Dutton GJ (ed) Glucuronic Acid. Academic Press, Free and Combined New York, pp 301-364
42. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E (2005) Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 12:887-916 (Pubitemid 40443846)
43. Nicolaides DN, Fylaktakidou KC, Litinas KE, Hadjipavlou-Litina D (1996) Synthesis and biological evaluation of some 4-(isoxazolinyl or 1,2,4-oxadiazolyl) coumarins. J Heterocycl Chem 33:967-971 (Pubitemid 26279915)
44. Burgart YV, Shcherbakov KV, Saloutin VI, Chupakhin ON (2004) 5,6,7,8-Tetrafluoro-4-hydroxycoumarin derivatives in reactions with o-phenylenediamin. Russ Chem Bul 53:1237-1239
45. Lu J, Li Y, Bai Y, Tian M (2004) Green chemistry approaches to the synthesis of 5-arylidenethiobarbituric acids by a condensation reactions between aromatic aldehydes and thiobarbituric acid: comparison of water, microwave irradiation, and grinding. Heterocycles 63:583-589
46. Ferreira RS, Bryant C, Ang KKH, McKerrow JH, Shoichet BK, Renslo AR (2009) Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem lett 52:5005-5008